Moderna’s Ebola Phase 1 Trial Signals Platform Broadening, Not Immediate Revenue Boost
Moderna has initiated a Phase 1 trial for mRNA-1469, targeting Bundibugyo ebolavirus (BDBV), supported by a $50 million CEPI grant and occurring as a real-world outbreak in the DRC registers 3,748 confirmed cases. The move strengthens the company’s mRNA platform story but is unlikely to drive near-term revenue or a sharp stock re-rating.